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Abstract
Background: Current clinical guidelines recommend that hormone receptor–positive breast cancer survivors take adjuvant
hormonal therapy (AHT) for 5 to 10 years, following the end of definitive treatment. However, fewer than half of patients adhere
to the guidelines, and suboptimal adherence to AHT is associated with an increased risk of breast cancer mortality. Research has
extensively documented sociodemographic and disease-specific factors associated with adherence to AHT, but very little evidence
exists on behavioral factors (eg, knowledge, patient-provider communication) that can be modified and targeted by interventions.
Objective: The goal of this study is to develop and test a theory-based, multilevel intervention to improve adherence to AHT
among breast cancer survivors from racially and socioeconomically disadvantaged backgrounds (eg, Medicaid-insured). The
specific aims are to (1) explore multilevel (eg, patient, health care system) factors that influence adherence to AHT; (2) develop
a theory-based, multilevel intervention to improve adherence to AHT; and (3) pilot test and evaluate the intervention developed
in Aim 2.
Methods: For Aim 1, we will recruit breast cancer survivors and health care professionals to participate in semistructured
interviews to gain their perspectives about barriers and facilitators to AHT use. We will conduct a directed content analysis of
the Aim 1 qualitative interview data. For Aim 2, we will integrate Aim 1 findings and current literature into the design of a
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multilevel intervention using an Intervention Mapping approach. For Aim 3, we will recruit Medicaid-insured breast cancer
survivors to assess the feasibility of the pilot intervention.
Results: From May 2016 to July 2018, we completed interviews with 19 breast cancer survivors and 23 health care professionals
in South Carolina. We will conduct a directed content analysis of the qualitative interview data. Results from this analysis will
be used, in combination with current literature, to design (Aim 2) and pilot test a theory-based multilevel intervention (Aim 3)
in Summer 2021. Results of the pilot are expected for Fall 2021.
Conclusions: This study will provide a deeper understanding of how to improve adherence to AHT, using a novel and multilevel
approach, among socioeconomically disadvantaged breast cancer survivors who often experience disproportionate breast cancer
mortality.
International Registered Report Identifier (IRRID): DERR1-10.2196/17742
(JMIR Res Protoc 2020;9(9):e17742) doi: 10.2196/17742
KEYWORDS
breast neoplasms; medicaid; medication adherence; vulnerable populations; hormonal therapy; endocrine therapy; qualitative
methods

Introduction
Background
Adjuvant hormonal therapy (AHT) has been shown to
significantly reduce recurrence and mortality rates among
women diagnosed with hormone receptor–positive (HR+) breast
cancer [1]. Current clinical guidelines for women diagnosed
with early stage (stages I-III) HR+ breast cancer recommend
up to 10 years of AHT with tamoxifen or an aromatase inhibitor
(AI), following surgery, chemotherapy and/or radiation, as
indicated. [2,3]. However, although AHT is considered the
standard of care for breast cancer, reports show that only about
50% of women complete treatment as recommended [4,5].
Systematic reviews show that sociodemographic factors, such
as race and age, are associated with treatment adherence. In
contrast, there is limited evidence about psychosocial or
behavioral factors that could be targeted with interventions
[4,6,7]. Additionally, previous studies that have examined
modifiable factors suggest that negative beliefs about AHT,
limited social support, low decisional balance scores and poor
patient-provider communication are all negatively associated
with therapy adherence [8-12]. Early discontinuation of and
poor adherence to AHT have been significantly associated with
disease progression and increased morality rates [5,13].
The problem of suboptimal adherence to AHT is important for
three key reasons. First, roughly 75% of diagnosed breast
cancers are HR+ [14], meaning that adherence to AHT is critical
for extending the survival of the majority of breast cancer
survivors. Second, studies show that differences in treatment,
including AHT use, significantly contribute to persistent racial
disparities observed in breast cancer mortality rates between
Black and White women [15,16]. This disparity increases for
women who are socioeconomically disadvantaged [17,18].
Third, rates of adherence to AHT are lowest among financially
disadvantaged populations versus other population–based
groups. For example, only 58% of Medicaid-insured women
adhered to AHT in the first year [19], compared to 80%-85%
in privately insured populations [20,21]. Hershman et al [22]
recently found that low annual household income (<US $40,000)
significantly decreased the odds of Black women adhering to
https://www.researchprotocols.org/2020/9/e17742
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AHT compared to White women. Therefore, the improvement
of adherence to AHT among socioeconomically disadvantaged
Black women with breast cancer is critical to increase their
survival rate as well as to close the gap on racial disparities in
breast cancer treatment.

Project Goal and Innovation
The overall goal of this study is to improve adherence to AHT
among breast cancer survivors from racially and
socioeconomically disadvantaged backgrounds. The specific
aims of this study are as follows: (1) explore patient, health care
system, and structural factors that may influence adherence to
AHT; (2) develop a theory-based, multilevel intervention
program to improve adherence to AHT; and (3) pilot and
evaluate the intervention program designed in Aim 2.
This project will incorporate principles of health communication
theory into the development and testing of the proposed
multilevel intervention program. The field of health
communication has been nationally prioritized as a strategy to
improve individual and population health [23]. Health
communications reflect an ecological perspective which posits
that individual health beliefs and behaviors are influenced by
the broader social environment. Thus, effective public health
communication can improve health behaviors by using strategies
that consider multiple levels of influence (eg, intrapersonal,
interpersonal, community) [24]. The use of health
communication theory in this study represents a novel approach
to fill a gap in the literature on how to apply theory in multilevel
interventions. Furthermore, the application of theory will yield
a practical framework for how to use health communication
theoretical constructs to determine appropriate communication
strategies (eg, knowledge, attitudes) that will target factors at
multiple levels known to influence AHT adherence, and how
to test them in a multilevel intervention.

Methods
Study Overview
This project received funding from the National Cancer Institute
of the National Institutes of Health (2015-2020). The proposed
research will address concepts proposed by the World Health
JMIR Res Protoc 2020 | vol. 9 | iss. 9 | e17742 | p. 2
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Organization’s (WHO) Multidimensional Adherence Model
Framework [25] and the Multi-level Context of Cancer Care
Model [26] (Table 1). This adapted framework shows how
factors are nested within multiple levels to influence AHT
adherence and can be useful for designing and targeting
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multilevel interventions. The formative, in-depth, semistructured
interviews (Aim 1, Years 1-2) will constitute the basis for the
development of culturally appropriate messaging and content
of the multilevel intervention (Aim 2; Year 2) to be pilot-tested
and evaluated in Year 3 (Aim 3).

Table 1. Modifiable factors at multiple levels that influence adherence to adjuvant hormonal therapy [27-29].
Level and factors

Related factors

Potential interventions

Patient

•

Psychosocial factors

•

Education + behavioral support

•

Knowledge, beliefs, attitudes

•

Case management

•

Illness perceptions

•

Pharmacist-led, multicomponent intervention

•

Family dynamics

•

Family/dyadic education

•

Friends, network support

•

AHT recommendations

•

Enhance skill mix/competencies of care team

•

AHT fill interval

•

Reminders

•

Communication preferences/styles

•

Education on effective patientcentered communication + behavior management

•

Perceptions/bias

•

Cost of AHT

•

Reduced out-of-pocket expenses

•

National/state/local policy

•

Public health insurance coverage

•

Distance to health/pharmacy
services

Family/social support

Health care system/health care team

Policy/structural/cultural

Aim 1. Explore Patient, Health Care System, and
Structural Factors That May Influence Adherence to
AHT
Study Design
Study Aim 1 will explore patient, health care system, and
structural factors that influence adherence to AHT (Years 1-2).
To achieve this aim, in-depth, semistructured qualitative
interviews will be conducted with health care professionals who
work in oncology settings and with breast cancer survivors. For
purposes of this research, we define a “breast cancer survivor”
as anyone who has been diagnosed with invasive breast cancer.

Health Care Professional Recruitment and Eligibility
Health care professionals will be recruited to participate in
qualitative interviews. The study will target health professionals
from key networks and organizations in South Carolina,
including professional organizations (eg, oncology nursing,
oncology social work), cancer centers and South Carolina’s
cancer coalition and department of health. The primary method
of recruitment will be through email invitation letters sent by
https://www.researchprotocols.org/2020/9/e17742
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the study’s principal investigator (PI).The invitation letter will
describe the study aims, study procedures, funding source, and
institutional review board approval protocol information.
Interested health care professionals will be able to contact the
study PI directly by telephone or email. The PI will schedule
an interview at a time and location convenient to the potential
participants to determine their eligibility for the study. Eligibility
requirements will include (1) being employed as a health care
professional (ie, physicians, nurses, pharmacists, social workers,
patient navigators); (2) currently working with breast cancer
patients, for example in an oncology setting, such as a cancer
center or hospital; and (3) age ≥ 21 years.

Health Care Professional Data Collection
Before the interview, health care professionals will be asked to
complete a brief questionnaire about their personal (eg, gender,
age) and professional (eg, current job title, type of health care
professional, health care setting) information. The PI will
conduct all interviews using a guide developed by the study
team. Key topics include: (1) major barriers to AHT adherence;
(2) organizational resources to support posttreatment (eg,
surgery, chemotherapy) of breast cancer survivors; (3)
JMIR Res Protoc 2020 | vol. 9 | iss. 9 | e17742 | p. 3
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communication among health care team members; (4)
communication with patients and their families; and (5)
organizational strategies for addressing problems with AHT
adherence. Participants will receive a US $50 cash stipend for
their time and effort. At the end of the interview, participants
will be asked for their contact information if they are willing
to participate in a follow-up feedback session, which will serve
to inform the development of a subsequent intervention. All
interviews will be digitally recorded and field notes will be
taken.

Breast Cancer Survivor Recruitment and Eligibility
Breast cancer survivors will be recruited from the South Carolina
Oncology Associates (SCOA) and the Gibbs Cancer Center and
Research Institute (GCCRI). Eligibility requirements include:
(1) age≥21 years; (2) diagnosed with HR+, invasive breast
cancer; (3) having medical records that confirm the prescription
of any hormonal treatment (anastrozole, exemestane, letrozole,
tamoxifen) at any point after diagnosis; (4) eligible for or
enrolled in South Carolina Medicaid program; and (5) being
able to speak and read in English.
To recruit participants, we will apply a recruitment model
developed by Heiney and colleagues [30], which combine social
marketing with relationship building. The PI and a research
assistant will work with SCOA and GCCRI staff to identify
participants who meet the study eligibility criteria using
electronic medical records. SCOA patients will be mailed a
personal invitation letter from the PI explaining the goals of the
study, including a Frequently Asked Questions document that
addresses potential concerns of research participants. The letter
will include a phone number to call if the participant prefers
not to be contacted. Within 3-5 days after the recruitment letter
is mailed, the PI or research assistant will contact the participant
by phone to provide them with an overview of the study. If the
participant expresses interest in the study, the PI or research
assistant will verify the participant’s study eligibility. If
eligibility is met, an interview appointment will be scheduled
at a time and location convenient to the participant. If a
participant is not eligible, the PI or research assistant will let
the participant know that they did not meet the study criteria
and will thank them for their interest in participating.
At GCCRI, designated staff will contact potentially eligible
breast cancer survivors by phone and provide them with an
overview of the study. If the participant shows interest in the
study, GCCRI staff will then ensure the participant meets study
eligibility. If eligibility is met, GCCRI staff will request verbal
consent by phone and set up an interview appointment at
GCCRI. Interested and eligible participants will be mailed an
“Appointment Form” confirming the date, time, and location
of the interview; a copy of the informed consent; and the
Frequently Asked Questions document.

Breast Cancer Survivor Data Collection
Interviews with participants recruited from SCOA will be
scheduled and conducted at a location (eg, home, library) and
time convenient to the participant, while GCCRI participant
interviews will be scheduled in person and onsite at GCCRI.
Before the interviews, the following informed consent process
https://www.researchprotocols.org/2020/9/e17742
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will be conducted: a research team member (PI or research
assistant) will read aloud a consent form that will inform the
participant about the following components of the study: title
of the research project, the identity of the project PIs and their
respective contact information, an introduction about the study,
the aims of the study, reason for the project, a summary of why
the individual has been asked to participate, a description of the
study procedures (ie, audiotaping of interviews), an outline of
any risks and/or benefits, an overview of how confidentiality
will be maintained, a discussion of any benefits, and a method
of securing additional information or asking questions. After
the consent form is read aloud and the participant agrees to
participate in the study, the research team member and
participant will sign and date the form. Participants will be given
a copy of the form for their records.
Following consent, participants will be asked to complete a
brief information form about their personal information (eg,
age, race, marital status), hormonal therapy (eg, type of drug,
daily use), and type of AHT resources used and preferred. The
research team will conduct all interviews using a semistructured
interview guide. Breast cancer survivors will be asked to
describe their experiences with AHT, including experiences
communicating with health care professionals about AHT, and
strategies used for addressing AHT nonadherence. All
participants will be given a US $50 cash stipend for their time
and effort. At the end of the interview, participants will be asked
if they are willing to participate in the intervention development
phase of this study (Aim 2).

Data Analysis of Interviews
All interviews will be recorded and transcribed verbatim by a
professional transcription service. Each participant’s audio file
and transcript will be assigned the same unique identifier as
their corresponding brief questionnaire. Quality control checks
will be conducted while reviewing the transcripts to ensure that
no personal identifiers are used. Audiotaped transcripts and
field notes will be used for data analyses. Transcripts will be
independently read and reviewed to check for accuracy and
authenticity.
To identify potential modifiable factors and future intervention
targets for Aim 2, Assarroudi et al’s [31] qualitative content
analysis approach will be used to analyze interview transcripts.
The PI will develop a preliminary codebook of main categories
and subcategories derived from the WHO Multidimensional
Adherence Model Framework [25] and Multilevel Context of
Cancer Care [26]. The PI will work with other team members
to discuss the codebook as well as the final main categories and
subcategories and their related meanings. The PI and two other
research team members will independently read and code a
selection of transcripts using the preliminary codebook.
Following this initial coding, all team members will meet,
compare coding results, and discuss differences in coding
interpretations and concerns with the preliminary codebook.
The PI will revise the codebook as needed. Once the codebook
is finalized, a research assistant who is knowledgeable in the
study topic area will, independently, code all the transcripts,
and the PI will code a random sample of the transcripts. The PI
and research assistant will then meet and discuss coded
JMIR Res Protoc 2020 | vol. 9 | iss. 9 | e17742 | p. 4
(page number not for citation purposes)

JMIR RESEARCH PROTOCOLS
transcripts, reach a consensus among any discrepancies and
calculate intercoder agreement [32].

Aim 2. Develop a Theory-based, Multi-level
Intervention Program to Improve Adherence to AHT
Overview of Intervention Development Via Data
Integration/synthesis and Intervention Mapping
Multiple sources will be used for the development of a
theory-based, multilevel intervention program, including
findings from Aim 1, current scientific literature, insights from
participant feedback sessions (described below), and expertise
of the project mentoring team. After analyzing the qualitative
data from the breast cancer survivor and health care professional
interviews, we will develop a modified, data-informed logic
model of potential interventions aimed at health care
professionals and their organizations, and survivors and their
family/social support. Logic models, representing an outcomes
hierarchy, will assist with a broad understanding of the
components of each potential intervention [33]. Potential
intervention strategies are shown in Table 1 [27-29]. The
research team will systematically review and compare findings
from the survivor and health care professional qualitative
interviews and quantitative questionnaire data. Of interest is
not only the variation within the survivor and health care
professional groups, but also the variation between the survivor
and health care professional reports. We will, therefore, identify
themes that occur within and across groups. We will employ a
logic model based on the PRECEDE approach [34] to illustrate
survivors’ experiences with AHT and how knowledge,
perceptions and attitudes at different levels impact their ability
to adhere to AHT. We will apply appropriate multi-level theories
to refine the intervention strategies and messages [35-37].

Validation of Formative Data and Intervention Design
Through Participant Feedback Session
From the group of participants that agreed to participate in a
follow-up feedback session, we will select a purposive sample
of breast cancer survivors (n=5; and their designated family
member/friend, n=5) and health care professionals (n=5), based
on their brief questionnaire and interview responses. We will
host two, 1 to 2 hours feedback sessions: one for breast cancer
survivors and their family member/social support, and another
one for health care professionals. The feedback sessions will
provide participants with the opportunity to judge the accuracy
and credibility of the qualitative research findings, as well as
to provide alternative interpretations and explanations when
necessary [38]. We will also discuss any differences of opinion
that may appear between the survivor and health care
professional interviews to reach a resolution. Participants will
receive US $50 and a light meal for their time and effort upon
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completion of the session. The project mentoring team will
provide guidance on how to refine the intervention design based
on the data from the feedback sessions and resolve any data
discrepancies.

Results
The institutional review boards of the University of South
Carolina, Prisma Health (formerly Greenville Health System)
and Spartanburg Regional Hospital System reviewed the study
protocols for Aim 1 and determined that they were exempt from
human research subject regulations. Qualitative data collection
for Aim 1 began in May 2016 and has been completed as of
July 2018. A total of 19 breast cancer survivors and 23 health
care professionals have been interviewed. Qualitative data
analysis will be completed by December 2020. Results from
this analysis will be used, in addition to current literature, to
design (Aim 2) and pilot test a theory-based multilevel
intervention (Aim 3) by Summer 2021. Multiple sources will
be used for the development of a theory-based, multilevel
intervention, including findings from Aim 1, current scientific
literature, insights from participant feedback sessions (Aim 2),
expertise of the research team, and trainings from the Multilevel
Intervention Training Institute at the National Cancer Institute.

Discussion
Findings from this research will help fill a gap in our current
understanding of underlying modifiable factors that influence
adherence to AHT, particularly among understudied disparate
populations [4]. To our knowledge, no previous study has
applied a multi-level intervention approach to improve
adherence to AHT [39]. Applying this approach to the cancer
treatment and survivorship phases of the cancer control
continuum is novel because most multi-level research in this
area focuses on prevention and screening [26,40]. There is a
similar pattern within the field of breast cancer research, where
there are fewer intervention studies that focus on improving
breast cancer treatment outcomes, compared to screening
[41,42]. Among the studies that focus on improving adherence
to AHT, few have found significant intervention effects
[39,43-45] or are currently analyzing data [46].
In conclusion, achieving the proposed aims will contribute to
the scientific community’s growing interest in multilevel
intervention design and analyses; describe relationships between
modifiable patient, family/social support, and health care
system/team factors and adherence to AHT; and identify feasible
intervention strategies for improving adherence to AHT among
breast cancer survivors from racially and socioeconomically
disadvantaged backgrounds.
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